Shots:

• The P-III (METIS) study assesses stereotactic radiosurgery with/without TTFields therapy vs SoC in patients (n=298) with 1-10 brain metastases from NSCLC
• The study met the 1EP demonstrating a median time to intracranial progression of 21.9mos. vs 11.3mos. and median TTFields therapy treatment duration of 16wks. with a median usage of 67%. The tolerability of TTFields was consistent with the prior evaluations showing sustained quality of life & neurocognitive function
• The preliminary analysis of 2EPs incl. time to neurocognitive failure, OS & radiological response rate was not significant while time to distant progression & quality of life were in favor of TTFields therapy. Further evaluation is underway

Ref: Novocure | Image: Novocure

Related News:- Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com